Nature Communications (Apr 2020)
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model
- Vincent Faugeroux,
- Emma Pailler,
- Marianne Oulhen,
- Olivier Deas,
- Laura Brulle-Soumare,
- Céline Hervieu,
- Virginie Marty,
- Kamelia Alexandrova,
- Kiki C. Andree,
- Nikolas H. Stoecklein,
- Dominique Tramalloni,
- Stefano Cairo,
- Maud NgoCamus,
- Claudio Nicotra,
- Leon W. M. M. Terstappen,
- Nicolo Manaresi,
- Valérie Lapierre,
- Karim Fizazi,
- Jean-Yves Scoazec,
- Yohann Loriot,
- Jean-Gabriel Judde,
- Françoise Farace
Affiliations
- Vincent Faugeroux
- INSERM, U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”
- Emma Pailler
- INSERM, U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”
- Marianne Oulhen
- Gustave Roussy, Université Paris-Saclay, “Circulating Tumor Cells” Translational Platform, CNRS UMS3655—INSERM US23 AMMICA
- Olivier Deas
- XenTech
- Laura Brulle-Soumare
- XenTech
- Céline Hervieu
- INSERM, U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”
- Virginie Marty
- Gustave Roussy, Université Paris-Saclay, Experimental and Translational Pathology Platform, CNRS UMS3655–INSERM US23 AMMICA
- Kamelia Alexandrova
- Gustave Roussy, Université Paris-Saclay, Department of Cell Therapy
- Kiki C. Andree
- Medical Cell Biophysics Group, Technical Medical Centre, Faculty of Science and Technology, University of Twente
- Nikolas H. Stoecklein
- Department of General, Visceral and Pediatric Surgery, Medical Faculty, University Hospital of the Heinrich-Heine-University Düsseldorf
- Dominique Tramalloni
- Gustave Roussy, Université Paris-Saclay, Department of Cell Therapy
- Stefano Cairo
- XenTech
- Maud NgoCamus
- Gustave Roussy, Université Paris-Saclay, Department of Cancer Medicine
- Claudio Nicotra
- Gustave Roussy, Université Paris-Saclay, Department of Cancer Medicine
- Leon W. M. M. Terstappen
- Medical Cell Biophysics Group, Technical Medical Centre, Faculty of Science and Technology, University of Twente
- Nicolo Manaresi
- Menarini Silicon Biosystems S.p.A
- Valérie Lapierre
- Gustave Roussy, Université Paris-Saclay, Department of Cell Therapy
- Karim Fizazi
- INSERM, U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”
- Jean-Yves Scoazec
- Gustave Roussy, Université Paris-Saclay, Experimental and Translational Pathology Platform, CNRS UMS3655–INSERM US23 AMMICA
- Yohann Loriot
- Gustave Roussy, Université Paris-Saclay, Department of Cancer Medicine
- Jean-Gabriel Judde
- XenTech
- Françoise Farace
- INSERM, U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”
- DOI
- https://doi.org/10.1038/s41467-020-15426-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
Better tumor models are needed for the neuroendocrine subtype of castration resistant prostate cancer (CRPC-NE). Here, the authors develop patient-derived model from circulating tumor cells of a CRPC-NE patient, and provide insights on the sequential acquisition of driver gene mutations promoting NE transdifferentiation.
